EDAP is a global leader in therapeutic ultrasound. The company markets its Ablatherm for high-intensity, focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment of prostate cancer is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects.

The company announced today that it received CE Mark (European regulatory approval) for Focal.One, its new and innovative robotic HIFU device dedicated to focal therapy of prostate cancer while preserving patient quality of life. Utilizing a focal therapy approach to target the cancer cells within the prostate gland is gaining wider acceptance in the global urological community.

EDAP’s Focal.One is the first device fully dedicated to the focal approach to prostate cancer therapy. It combines the three essential components to efficiently perform a focal treatment: state-of-the-art imaging to localize tumors with the use of MRI technology combined with real-time ultrasound, utmost precision of HIFU treatment focused on identified cancer areas only, and immediate feedback on treatment efficacy utilizing contrast-enhanced ultrasound imaging.

The CE Mark positions the company’s Focal.One device for full commercialization in Europe and in many other countries. EDAP’s unique and exclusive range of HIFU products offers perhaps the widest array of treatment options to patients with prostate cancer. For additional information about EDAP TMS and its entire product line, please visit www.edap-tms.com or www.hifu-planet.com.

Let us hear your thoughts below: